What is driving GV.PA stock’s intraday volume?

The main driver is elevated trading interest in a very low-price, thinly liquid stock. Volume at **38,489,238** versus a **14,217,513** average suggests trade flows or news scraping the order book, not immediate fundamental change.

How does Genomic Vision SA’s valuation look?

Valuation metrics show distress: negative EPS (-0.11), negative PE, market cap **EUR 693,191**, and EV-to-sales **1.60**. These point to a speculative profile with limited near-term fundamental support.

What is Meyka AI’s grade for GV.PA stock?

Meyka AI rates GV.PA with a score out of 100: **62.56 (Grade B) — Suggestion: HOLD**. The grade factors include benchmark and sector comparison, financial growth, key metrics, and analyst consensus.

Should traders enter GV.PA stock on intraday spikes?

Intraday entries are high risk due to wide spreads and volatility. If trading, use tight stops, small position sizes, and confirm order book depth before committing capital.

EU Stocks

GV.PA Genomic Vision SA (EURONEXT) intraday most active 09 Mar 2026: heavy volume signals trader interest

ByHuzaifa Zahoor March 9, 2026

GV.PA stock is trading at EUR 0.0018 on EURONEXT on 09 Mar 2026, up 5.88% intraday as volume surges to 38,489,238 shares. This spike makes Genomic Vision SA (GV.PA) one of Europe’s most active small-cap names today. The move follows thin liquidity history and heavy relative volume of 2.71x versus the 14,217,513 average, prompting short-term traders to reprice risk and opportunity in the Healthcare diagnostics name.